Home›Trial›NCT04124406
NCT04124406ACTIVE NOT RECRUITING

Voyage: Real-World Impact of the Multi-target Stool DNA Test on CRC Screening and Mortality

Study Summary

The purpose of this study is to gather information about the long term health of people who have been prescribed the Cologuard test, which is used for colorectal cancer (CRC) screening.

Conditions
Colon Cancer
Interventions / Drugs
Cologuard
View on ClinicalTrials.gov ↗
Sponsor
EXAS
Exact Sciences
Diagnostics
D43/100
Study Details
Enrollment150000 participants
Primary Completion—
Lead SponsorExact Sciences Corporation
Data Retrieved2026-04-11 04:13:38.204256+00:00
What This Trial Means for Biotech Investors
Trial Phase Context
Status & Expected Data

Enrollment is complete. The trial is in its follow-up or data collection phase — a readout may occur on or near the primary completion date.

Enrolled: 150,000 participants
Sponsor Catalyst Profile

Exact Sciences (EXAS) is the sponsoring company for this trial. BiotechSign currently grades this company D (43/100) based on composite catalyst signals across its full pipeline. This trial is one data point in that overall catalyst picture.

EXAS Full Pipeline →All Companies →
Not financial advice. BiotechSign data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.